Podcast
The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest
Hosted by The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest · EN
This podcast delivers concise clinical updates in cardiology alongside insightful career stories from pharmacists in the field. Host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, CACP, provides essential knowledge and practical perspectives for pharmacy professionals specializing in cardiovascular care.
37episodes
Episodes
Newest firstAll episodes
17: New Frontiers in Hypertension Care: Insights from the KARDIA-3 and Bax Hypertension Trials
Oct 700:54:20Tap to summarizeKARDIA-3 Study KARDIA 3 Study Design KARDIA 2 Study BaxHTN Study Shelby Tungate Lopez, PharmD, CPP, BCACP, MPA is a clinical pharmacist practitioner at the UNC Eshelman School of Pharmacy. He can be reached on Linkedin @ShelbyTungateLopez, and more information can be found about his interests and work at his faculty page.
Transcribe →
16: Deconstructing Meta-Analyses From ESC 2025
Sep 2300:54:46Tap to summarizePooled Analysis From VICTOR and VICTORIA Trialsβ Blocker After Myocardial Infarction Meta Analysis
Transcribe →15: ESC 2025 Highlights: Insights on ALONE-AF and AQUATIC Trials
Sep 900:42:16Tap to summarizeHost Craig Beavers sits down with Lorenz van der Linden, a Belgian pharmacist, to dive deep into 2 groundbreaking trials from the European Society of Cardiology (ESC) 2025 Congress. They explore the ALONE-AF trial, which examined anticoagulation strategies for patients with atrial fibrillation after catheter ablation, and the AQUATIC trial, which investigated the role of aspirin in patients on oral anticoagulation. With their expert analysis, Craig and Lawrence break down the clinical implications, methodological nuances, and potential practice-changing insights from these important cardiovascular studies.Show notes: ALONE-AF findings AQUATIC findings
Transcribe →14: Sifting Through Discordant Data From ESC 2025
Sep 500:50:17Tap to summarizeFollowing the European Society of Cardiology Congress 2025, experts sat down again with host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-cards), CACP, to discuss key findings from the meeting. Kaitlin Hile, PharmD, BCCP; Robert Page, PharmD, MSPH, BCPS (AQ-cards), BCGP, FAHA, FHFSA, FCCP, FASHP; and Robert DiDomenico, PharmD, FCCP, FHFSA, FACC, reviewed new data from the meeting and parsed through their lingering questions. Show Notes: Beta-Blockers After Myocardial Infarction Without Reduced Ejection Fraction (REBOOT; NCT03596385) Beta-Blockers After Myocardial Infarction in Patients Without Heart Failure (BETAMI–DANBLOCK; NCT03646357, NCT03778554) Digitoxin in Patients With Heart Failure and Reduced Ejection Fraction (DIGIT-HF) Vericiguat in Patients With Chronic Heart Failure and Reduced Ejection Fraction (VICTOR): A Double-Blind, Placebo-Controlled, Randomized, Phase 3 Trial (NCT05093933)
Transcribe →13: From Guidelines to Action: Pharmacy’s Role in Hypertension Management
Aug 2600:40:40Tap to summarizeIn this episode, host Craig Beavers sits down with Gary Owen, clinical pharmacist and manager of Population Health Pharmacy Services at Vanderbilt University Medical Center, to discuss the newly updated ACC/AHA hypertension guidelines and what they mean for pharmacists. Gary shares how his team supports primary care providers across the state through collaborative practice agreements, innovative telephonic care models, and value-based care initiatives. The conversation explores how pharmacists can play a pivotal role in optimizing medication management, improving patient access, and driving better outcomes in chronic disease care.Read the guidelines here.
Transcribe →12: A New Joint Scientific Statement and What to Watch for at the European Society of Cardiology Congress 2025
Aug 12, 202500:27:04Tap to summarizeThis week, host Craig Beavers tackles the upcoming European Society of Cardiology (ESC) Congress 2025, taking place August 29 through September 1, 2025. Key data to keep an eye on will include the following: The VICTORION-Difference study of inclisiran in hyperlipidemia The Essence study of olezarsen in hypertriglyceridemia Multiple studies on early discontinuation of aspirin after percutaneous coronary intervention in high-risk acute coronary syndromes The DAPT-SHOCK-AMI trial of cangrelor in patients with cardiogenic shock related to acute myocardial infarction The ALONE-AF trial about stopping anticoagulation after successful atrial fibrillation ablation The ODYSSEY-HCM and MAPLE-HCM studies on mavacamten and aficamten in hypertrophic cardiomyopathy Stay tuned on upcoming episodes for deeper dives into these data and other key takeaways from ESC!
Transcribe →11: A Roundtable Discussion of Upcoming Hot Line Trials at ESC Congress 2025
Jul 29, 202501:06:24Tap to summarizeIn this episode, Kaitlin Hile, PharmD, BCCP; Robert Page, PharmD, MSPH, BCPS (AQ-cards), BCGP, FAHA, FHFSA, FCCP, FASHP; and Robert DiDomenico, PharmD, FCCP, FHFSA, FACC, sat down with host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-cards), CACP, for an exciting discussion of several Hot Line trials at the upcoming European Society of Cardiology Congress 2025. Learn more about the ESC Congress 2025 Hot Line sessions here.
Transcribe →10: COBRRA Trial Results Raise Questions About VTE Management
Jul 15, 202500:31:46Tap to summarizeThis week, host Craig Beavers sat down with Tara Lech, PharmD, CACP, director of anticoagulation services at Beth Israel Lahey Health, to discuss recent findings from the COBBRA trial, which compared bleeding risk with rivaroxaban versus apixaban.
Transcribe →9: An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial
Jul 1, 202500:44:50Tap to summarizeHost Craig Beavers sits down with Kazuhiko Kido, PharmD, a clinical associate professor at the West Virginia University School of Pharmacy, to discuss intravenous iron and its use in patients with heart failure, as well as findings from the FAIR-HF2 clinical trial.Show notes: Anker SD, Friede T, Butler J, et al. Intravenous ferric carboxymaltose in heart failure with iron deficiency. JAMA. 2025;333(22):1965-1976. doi:10.1001/jama.2025.3833 Kido K, Fang W, Broscious R, et al. Evaluation of a pharmacist-provider collaborative clinic for treatment of iron deficiency in patients with heart failure. Am J Health Syst Pharm. 2023;80(19):1326-1335. doi:10.1093/ajhp/zxad149 Kido K, Beavers CJ, Dulnuan K, et al. Management of iron deficiency in heart failure: practical considerations and implementation of evidence-based iron supplementation. JACC Heart Fail. 2024;12(12):1961-1978. doi:10.1016/j.jchf.2024.05.014 Scientific Statement on Diagnosis and Treatment of Iron Deficiency in Heart Failure Released by Heart Failure Society of America. News release. HFSA. May 2, 2023. Accessed June 27, 2025. Antrim A. Enhancing Patient Care in Heart Failure-Related Anemia Through Improved Communication, Monitoring, and Education. Pharmacy Times. March 17, 2025. Accessed June 27, 2025.
Transcribe →8: Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care
Jun 17, 202500:41:07Tap to summarizeHost Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, CACP, chats with Shannon Finks, PharmD, FCCP, BCPS, BCCP, AHSCP-CHC, president and director of pharmacy services at ZupMed in Memphis, Tennessee. Finks reviews exactly what concierge medicine is, as well as its role in cardio-kidney-metabolic health and her own research on compounded GLP-1 and GIP agonists in a pharmacist-managed cardiometabolic clinic.Show Notes: Finks SW, Benavides D, Martin AG, Carmon AS. Real-world observations of using compounded GLP-1 +- GIP agonists within a clinical pharmacist-managed cardiometabolic clinic. J Am Col Clin Pharm. 2024. doi:10.1002/jac5.2071 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221-2232. doi:10.1056/NEJMoa2307563 ZupMed.com
Transcribe →